- Home
- Eurosurveillance
- Previous Issues
- Volume 29, Issue 8, 22/Feb/2024
Eurosurveillance - Volume 29, Issue 8, 22 February 2024
Volume 29, Issue 8, 2024
- Rapid communication
-
-
-
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Marine Maurel , Jennifer Howard , Esther Kissling , Francisco Pozo , Gloria Pérez-Gimeno , Silke Buda , Noémie Sève , Adele McKenna , Adam Meijer , Ana Paula Rodrigues , Iván Martínez-Baz , Ivan Mlinarić , Neus Latorre-Margalef , Gergő Túri , Mihaela Lazăr , Clara Mazagatos , Aitziber Echeverria , Stephen Abela , Marc Bourgeois , Ausenda Machado , Ralf Dürrwald , Goranka Petrović , Beatrix Oroszi , Ligita Jancoriene , Alexandru Marin , Petr Husa , Roisin Duffy , Frederika Dijkstra , Virtudes Gallardo García , Luise Goerlitz , Vincent Enouf , Charlene Bennett , Mariëtte Hooiveld , Raquel Guiomar , Camino Trobajo-Sanmartín , Vesna Višekruna Vučina , Tove Samuelsson Hagey , Ana Sofía Lameiras Azevedo , Jesús Castilla , Gerd Xuereb , Bénédicte Delaere , Verónica Gómez , Kristin Tolksdorf , Sabrina Bacci , Nathalie Nicolay , Marlena Kaczmarek , Angela MC Rose and on behalf of the European IVE groupInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
-
-
-
Clinical isolates of ST131 blaOXA-244-positive Escherichia coli, Italy, December 2022 to July 2023
The dissemination of carbapenemase-producing Escherichia coli, although still at low level, should be continuously monitored. OXA-244 is emerging in Europe, mainly in E. coli. In Italy, this carbapenemase was reported from an environmental river sample in 2019. We report clinical isolates of OXA-244-producing ST131 E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131 E. coli, is of clinical relevance.
-
- Top
-
- Surveillance
-
-
-
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
BackgroundWastewater surveillance has expanded globally as a means to monitor spread of infectious diseases. An inherent challenge is substantial noise and bias in wastewater data because of the sampling and quantification process, limiting the applicability of wastewater surveillance as a monitoring tool.
AimTo present an analytical framework for capturing the growth trend of circulating infections from wastewater data and conducting scenario analyses to guide policy decisions.
MethodsWe developed a mathematical model for translating the observed SARS-CoV-2 viral load in wastewater into effective reproduction numbers. We used an extended Kalman filter to infer underlying transmissions by smoothing out observational noise. We also illustrated the impact of different countermeasures such as expanded vaccinations and non-pharmaceutical interventions on the projected number of cases using three study areas in Japan during 2021–22 as an example.
ResultsObserved notified cases were matched with the range of cases estimated by our approach with wastewater data only, across different study areas and virus quantification methods, especially when the disease prevalence was high. Estimated reproduction numbers derived from wastewater data were consistent with notification-based reproduction numbers. Our projections showed that a 10–20% increase in vaccination coverage or a 10% reduction in contact rate may suffice to initiate a declining trend in study areas.
ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available.
-
- Top
-
- Research
-
-
-
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
Hannah Chung , Michael A Campitelli , Sarah A Buchan , Aaron Campigotto , Natasha S Crowcroft , Jonathan B Gubbay , James KH Jung , Timothy Karnauchow , Kevin Katz , Allison J McGeer , J Dayre McNally , David C Richardson , Susan E Richardson , Laura C Rosella , Margaret L Russell , Kevin L Schwartz , Andrew Simor , Marek Smieja , Maria E Sundaram , Bryna F Warshawsky , George Zahariadis , Jeffrey C Kwong and on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) InvestigatorsBackgroundWaning immunity from seasonal influenza vaccination can cause suboptimal protection during peak influenza activity. However, vaccine effectiveness studies assessing waning immunity using vaccinated and unvaccinated individuals are subject to biases.
AimWe examined the association between time since vaccination and laboratory-confirmed influenza to assess the change in influenza vaccine protection over time.
MethodsUsing linked laboratory and health administrative databases in Ontario, Canada, we identified community-dwelling individuals aged ≥ 6 months who received an influenza vaccine before being tested for influenza by RT-PCR during the 2010/11 to 2018/19 influenza seasons. We estimated the adjusted odds ratio (aOR) for laboratory-confirmed influenza by time since vaccination (categorised into intervals) and for every 28 days.
ResultsThere were 53,065 individuals who were vaccinated before testing for influenza, with 10,264 (19%) influenza-positive cases. The odds of influenza increased from 1.05 (95% CI: 0.91–1.22) at 42–69 days after vaccination and peaked at 1.27 (95% CI: 1.04–1.55) at 126–153 days when compared with the reference interval (14–41 days). This corresponded to 1.09-times increased odds of influenza every 28 days (aOR = 1.09; 95% CI: 1.04–1.15). Individuals aged 18–64 years showed the greatest decline in protection against influenza A(H1N1) (aORper 28 days = 1.26; 95% CI: 0.97–1.64), whereas for individuals aged ≥ 65 years, it was against influenza A(H3N2) (aORper 28 days = 1.20; 95% CI: 1.08–1.33). We did not observe evidence of waning vaccine protection for individuals aged < 18 years.
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.
-
- Top
-
- Perspective
-
-
-
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany’s experience during the COVID-19 pandemic, July 2021 to March 2023
The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the country’s overall positive experience using the screening method, including its strengths and limitations, and provide practical guidance regarding a few issues, such as case definition stringency, testing behaviour, and data stratification, that require careful consideration during data analysis and the interpretation of the results.
-
- Top
-
- Author's correction
-
Volumes & issues
-
Volume 29 (2024)
-
Volume 28 (2023)
-
Volume 27 (2022)
-
Volume 26 (2021)
-
Volume 25 (2020)
-
Volume 24 (2019)
-
Volume 23 (2018)
-
Volume 22 (2017)
-
Volume 21 (2016)
-
Volume 20 (2015)
-
Volume 19 (2014)
-
Volume 18 (2013)
-
Volume 17 (2012)
-
Volume 16 (2011)
-
Volume 15 (2010)
-
Volume 14 (2009)
-
Volume 13 (2008)
-
Volume 12 (2007)
-
Volume 11 (2006)
-
Volume 10 (2005)
-
Volume 9 (2004)
-
Volume 8 (2003)
-
Volume 7 (2002)
-
Volume 6 (2001)
-
Volume 5 (2000)
-
Volume 4 (1999)
-
Volume 3 (1998)
-
Volume 2 (1997)
-
Volume 1 (1996)
-
Volume 0 (1995)
Most Read This Month
-
-
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Victor M Corman , Olfert Landt , Marco Kaiser , Richard Molenkamp , Adam Meijer , Daniel KW Chu , Tobias Bleicker , Sebastian Brünink , Julia Schneider , Marie Luisa Schmidt , Daphne GJC Mulders , Bart L Haagmans , Bas van der Veer , Sharon van den Brink , Lisa Wijsman , Gabriel Goderski , Jean-Louis Romette , Joanna Ellis , Maria Zambon , Malik Peiris , Herman Goossens , Chantal Reusken , Marion PG Koopmans and Christian Drosten
-
- More Less